UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION FOR THE YEAR ENDED JUNE 30, 2017Asset Acquisition Agreement • September 22nd, 2017 • Cesca Therapeutics Inc. • Laboratory apparatus & furniture
On July 7, 2017, Cesca Therapeutics, Inc. (“Cesca”), through its subsidiary ThermoGenesis Corp. (“ThermoGenesis”), entered into an Asset Acquisition Agreement (the “Asset Acquisition Agreement”) with SynGen, Inc. (“SynGen”), and pursuant to the terms of the Asset Acquisition Agreement, ThermoGenesis acquired on July 7, 2017 substantially all of SynGen’s operating assets, including its proprietary cell processing platform technology (the “Transaction”). The business acquired in the Transaction excludes certain assets and liabilities of SynGen that ThermoGenesis did not acquire under the Asset Acquisition Agreement including cash and cash equivalents, accounts receivable, certain prepaid expenses and other current assets, other assets, accounts payable and other accrued liabilities as described in the accompanying notes to the unaudited pro forma condensed combined financial statements.
